Dr Reddy’s Laboratories

Nifty Pharma tanks 4.33%, records worst intra-day fall since December; Dr Reddy’s plummets 10%

Nifty Pharma index came under attack from bears on Tuesday forcing the sectoral gauge to close 4.33% lower, the worst single-day fall recorded by the index since December last year.

Dr Reddy’s, IndiGo, Vodafone Idea, DLF, JSW Steel, Glenmark Life IPO, Axis Bank stocks in focus

Nifty futures were trading 26.50 points or 0.17 per cent up at 15,848 on Singaporean Exchange, indicating a positive start for BSE Sensex and Nifty 50 on Tuesday

Dr Reddy's, IndiGo, Vodafone Idea, DLF, JSW Steel, Glenmark Life IPO, Axis Bank stocks in focus

Cipla share price hits record high on DCGI nod to import Moderna vaccine to treat COVID-19; may rally 12% more

Cipla share price hit a new record high of Rs 997.20 apiece in intraday on BSE on Wednesday, after the DCGI approved the firm to import Moderna, a Covid-19 vaccine, with emergency use authorisation in India.

cipla, moderna, covid-19 vaccine

Shilpa Medicare share price surges 26% in 2 days on tie-up with Dr Reddy’s for Sputnik V COVID vaccine

Shilpa Medicare share price surged 13 per cent in intraday deals on BSE after the company tied up with Dr. Reddy's Laboratories (DRL) for production-supply of the Sputnik V, a COVID-19 vaccine.

SII has committed to make 100 million Covishield vaccines a month from June. It has started manufacturing the Novavax vaccine, in small batches, at its Pune plant, even as it awaits regulatory clearance in the US and subsequently in India.

Dr Reddy’s Laboratories rating – Add: A stable showing by the company

Covid vaccine to provide significant upside to earnings; TP up to Rs 5,848; ‘Add’ retained

dr reddy

Dr Reddy’s Q4 profit dips 29 pc to Rs 557 cr

Net sales however rose to Rs 4,608 crore in the quarter under review as compared with Rs 4,336.1 crore in the fourth quarter of 2019-20, Dr Reddy's Laboratories said in a regulatory filing.

L&T, Cipla, Lupin, Dr Reddy’s, Vedanta, GAIL, Tata Power, Reliance Infrastructure stocks in focus

Nifty futures were trading 191.50 points or 1.32 per cent higher at 14,699 on Singaporean Exchange, indicating a strong opening for BSE Sensex and Nifty 50

L&T, Cipla, Lupin, Dr Reddy's, Vedanta, stocks in focus

Vaccine approval positive for Dr Reddy’s but should you inject your portfolio with Sputnik V?

With Sputnik V covid-19 vaccine getting the Emergency Use Authorisation (EUA), Dr Reddy’s Laboratories stands to benefit after having secured exclusive marketing and distribution rights for the first 250 million doses of th

stock market, dr reddys

Dr Reddy’s Laboratories rating – Buy: API supplies for Vascepa are an issue

Gradual ramp-up of drug expected through FY22, with US revenues of $25 m; FY22e EPS down 1%; ‘Buy’ retained with TP of Rs 5,533

Pharma shares to continue surging despite rich valuations; HSBC lists top stock picks

Even after pharma stocks witnessed a massive bull run in 2020 and valuations seem quite rich at this juncture, global investment bank HSBC expects the momentum to continue.

Share Market Today, Share Market Live

Top stocks to buy: Axis Bank, Dr Reddy’s among 5 stocks that may rally 22% in new year 2021

On the market outlook in the New Year 2021, the brokerage firm expects the momentum to be maintained given the ultra-loose monetary policies of global central bankers.

stocks to buy, axis bank, wipro, bajaj auto

Stocks in focus: Tata Motors, Dr Reddy’s Lab, Reliance Capital, YES Bank, Vodafone Idea, bank stocks

Investors will keep tabs on stock-specific development, foreign fund flow, oil and rupee movement and other global cues.

sensex, nifty

Dr Reddy’s Lab shares hit new 52-wk high on patent suit settlement with Celgene; more than doubles in 6 months

Dr. Reddy's Laboratories shares have rallied 15.55 per cent, in comparison, S&P BSE Sensex gained just 1.14 per cent. The company announced the settlement of US Revlimid® (lenalidomide) capsules patent litigation with Celgen

Top FMCG, health, pharma stocks to buy: Unlock, improved economic activity to aid next rally

Indian share market benchmarks BSE Sensex and Nifty 50 gained nearly 5 per cent in June as compared to a 3 per cent rise in May

Top pharma stocks to buy: Pharma shares rally as coronavirus disrupts global supply chain

One sector whose shares are outperforming the benchmark stock indices and hitting new highs is the pharmaceutical sector. Given below are top five strong tactical buys from the pharma sector.

Dr Reddy’s to acquire Teva’s product portfolio for US Market

The portfolio being acquired is a mix of filed ANDAs pending approval and an approved ANDA. It also comprises complex generic products across diverse dosage forms

Dr Reddy’s Laboratories looks to acquire relevancy in the US; here’s how

DR Reddy’s Laboratories has entered into a definitive agreement with Israel-based Teva Pharmaceutical Industries and an affiliate...

Dr Reddy's Laboratories, Dr Reddy's, Dr Reddy's share price, Dr Reddy's XenoPort, XenoPort, XenoPort Dr Reddy's, business news

Dr Reddy’s to buy eight ANDAs in US for $350 mn

Dr Reddy's Laboratories has inked a pact with Teva Pharmaceutical and an affiliate of Allergan Plc to buy a portfolio of eight abbreviated new drug applications (ANDAs) in the US for $ 350 million (around Rs 2,300 crore) in c

dr reddy labs share price, bse sensex

US Consumer Commission seeks action against Dr Reddy Laboratories over packaging

The US Consumer Product Safety Commission (US CPSC) has approached the US Department of Justice seeking action against Dr Reddy's Laboratories in a 5-year old case involving packaging for five blister-packed prescription prod

dr reddy's labs shares

Dr Reddy’s Labs shares plunge on packaging lapses charges

Dr Reddy's Laboratories shares plunged as much as 2.24 per cent on Thursday after reports that the US Consumer Product Safety Commission charges company for packaging lapses in at least five prescription drugs.

dr reddy's labs shares

Dr Reddy’s launches Sernivo spray in the US market

Sernivo Spray, a prescription topical steroid... indicated for the treatment of mild to moderate plaque psoriasisin patients 18 years of age or older...

dr reddy's labs shares

DRL enters branded consumer health arena through acquisition of six OTC brands

DRL will build upon the sales and marketing efforts for these brands and continue to focus on their expansion into existing and new market channels

Dr Reddy’s Laboratories buys 6 OTC brands from Ducere Pharma

Dr Reddy’s Laboratories has acquired a portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain and dermatology categories.

Dr. Reddy's Laboratories shares Q1 numbers

Neutral rating on Dr Reddy’s; Weak Q4; sales down ~3% y-o-y

While long-term fundamentals remain intact, stock will stay range-bound in the near term

Dr Reddy's Laboratories, Dr Reddy's, Dr Reddy's share price, Dr Reddy's XenoPort, XenoPort, XenoPort Dr Reddy's, business news

Dr Reddy’s recalls 50k bottles of Ondansetron tabs in US

The ongoing recall was initiated on March 30, 2016

Income Tax Calculator, Budget 2019, How to Calculate Income Tax


Stock Market

Most Read


Top News


Related Articles